UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
JANX holding history
Janux Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
JANX overviewAll 13F holders of JANXFull Q2 2026 holdings
- Shares (Q2 2026)
- 150,701
- Value
- $2.31M
- % of portfolio
- <0.1%
- Quarters held
- 16
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 150,701 | $2.31M | <0.1% | −69,105−31.4% | Reduced | Holders |
| Q1 2026 | 219,806 | $3.06M | <0.1% | −370,254−62.7% | Reduced | Holders |
| Q4 2025 | 590,060 | $8.14M | <0.1% | +199,703+51.2% | Added | Holders |
| Q3 2025 | 390,357 | $9.54M | <0.1% | +97,824+33.4% | Added | Holders |
| Q2 2025 | 292,533 | $6.76M | <0.1% | −195,947−40.1% | Reduced | Holders |
| Q1 2025 | 488,480 | $13.2M | <0.1% | +263,390+117.0% | Added | Holders |
| Q4 2024 | 225,090 | $12.1M | <0.1% | +170,896+315.3% | Added | Holders |
| Q3 2024 | 54,194 | $2.46M | <0.1% | +3,326+6.5% | Added | Holders |
| Q2 2024 | 50,868 | $2.13M | <0.1% | +28,664+129.1% | Added | Holders |
| Q1 2024 | 22,204 | $836.0K | <0.1% | +22,204 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −841−100.0% | Sold out | Holders |
| Q1 2023 | 841 | $10.2K | <0.1% | +628+294.8% | Added | Holders |
| Q4 2022 | 213 | $2.81K | <0.1% | +213 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −3,500−100.0% | Sold out | Holders |
| Q1 2022 | 3,500 | $50.0K | <0.1% | −185−5.0% | Reduced | Holders |
| Q4 2021 | 3,685 | $73.0K | <0.1% | +185+5.3% | Added | Holders |
| Q3 2021 | 3,500 | $76.0K | <0.1% | +3,147+891.5% | Added | Holders |
| Q2 2021 | 353 | $9.00K | <0.1% | +353 | New | Holders |